JP2019518742A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518742A5
JP2019518742A5 JP2018559937A JP2018559937A JP2019518742A5 JP 2019518742 A5 JP2019518742 A5 JP 2019518742A5 JP 2018559937 A JP2018559937 A JP 2018559937A JP 2018559937 A JP2018559937 A JP 2018559937A JP 2019518742 A5 JP2019518742 A5 JP 2019518742A5
Authority
JP
Japan
Prior art keywords
antibody
use according
isotype
active fragment
immunologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518742A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031673 external-priority patent/WO2017196793A1/en
Publication of JP2019518742A publication Critical patent/JP2019518742A/ja
Publication of JP2019518742A5 publication Critical patent/JP2019518742A5/ja
Pending legal-status Critical Current

Links

JP2018559937A 2016-05-09 2017-05-09 Cd47抗体およびその使用方法 Pending JP2019518742A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333631P 2016-05-09 2016-05-09
US62/333,631 2016-05-09
PCT/US2017/031673 WO2017196793A1 (en) 2016-05-09 2017-05-09 Cd47 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2019518742A JP2019518742A (ja) 2019-07-04
JP2019518742A5 true JP2019518742A5 (enExample) 2020-06-18

Family

ID=60267183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559937A Pending JP2019518742A (ja) 2016-05-09 2017-05-09 Cd47抗体およびその使用方法

Country Status (6)

Country Link
US (2) US20200255515A1 (enExample)
EP (1) EP3454900A4 (enExample)
JP (1) JP2019518742A (enExample)
AR (1) AR112048A1 (enExample)
TW (1) TW201741340A (enExample)
WO (1) WO2017196793A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
WO2019086573A1 (en) 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN112566938B (zh) 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技(成都)有限公司 一种阻断CD47和SIRPα相互作用的抗体
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CN114615989A (zh) * 2019-07-17 2022-06-10 里兰斯坦福初级大学理事会 用于治疗癌症的靶向整联蛋白的打结素-fc融合体与抗cd47抗体的组合
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
KR20230079393A (ko) * 2020-09-28 2023-06-07 상하이 헨리우스 바이오테크, 인크. 항 cd47 항체 및 사용 방법
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR20230121772A (ko) 2020-12-18 2023-08-21 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이적 항체
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
US11807685B2 (en) * 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN119998319A (zh) 2022-06-16 2025-05-13 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
CN118221812A (zh) * 2022-12-14 2024-06-21 上海迈石生物技术有限公司 一种靶向cd47的单克隆抗体及其应用
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309246A1 (en) * 2011-02-02 2013-11-21 The Trustees Of Princeton University Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
ME03512B (me) * 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
BR112015030514A2 (pt) * 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis

Similar Documents

Publication Publication Date Title
JP2022031635A5 (enExample)
HRP20191609T1 (hr) Protein
CN110366560A (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
JP2014240385A5 (enExample)
JP2009114201A5 (enExample)
MY205774A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP2017149726A5 (enExample)
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
JP2015534579A5 (enExample)
FI3569620T3 (fi) Ihmisen cgrp-reseptoria sitovat vasta-aineet
JP2017071606A5 (enExample)
WO2006089133A3 (en) Anti-cd19 antibodies and uses in oncology
JP2015502138A5 (enExample)
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
JP2015520758A5 (enExample)
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
JP2012121878A5 (enExample)
HRP20221088T1 (hr) Protutijela i postupci uporabe
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
JP2016094424A5 (enExample)
EP4032550A3 (en) Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
HRP20170687T1 (hr) Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.